Aptose Expanded Access Policy

At Aptose Biosciences, we are developing a pipeline of precision oncology therapies with the potential to serve specific populations of cancer patients.

We are committed to conducting clinical trials in an ethical manner to assure the safety and efficacy of our investigational therapies and obtain the necessary regulatory approvals that could allow patients broad access to our products. We believe that enrolling patients in our clinical trials is the most appropriate way to achieve this goal and serve the needs of the greatest number of patients. Therefore, at this time, our investigational drugs are not offered outside of our clinical trials, and we do not have an expanded access program.

We welcome patients to participate in our clinical trials. To learn more about our clinical trials, including eligibility requirements, please contact your treating physician and visit ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world.

Links to HM43239 and Luxeptinib (CG-806) Aptose clinical trials are provided below:



Luxeptinib (CG-806):



For any additional questions, please contact us at +1 858-926-2730.